development manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.read morecompany overviewcancer immunotherapyinfectious diseasesmanufacturingcancer immunotherapymanagementexecutive managementboard of directorscompany overview corporate governanceboard composition and workboard committeesboard committee chartersdiversity in the boardremuneration policyarticles of associationboard committee charters corporate social responsibility pipelinepipelineour pipeline has multiple clinical stage development programs including three phase 3 programs.read moreimvamuneabout smallpoxpublicationsmva bn filoabout filoviruspublicationsmva bn rsvabout rsvmva bn hpv prostvacabout prostate cancerphase 3 clinical studycombination studiespublicationscv301publicationsmva bn brachyurypublications technologymva bnvf tricomclinical trials investorsinvestorsbavarian nordic is committed to providing our shareholders and the media with reliable and transparent information about our business development programs and results in an open and timely mannerread morenewssubscribeevents & presentationsannual report 2015events & presentations share informationstock chartanalystsownershipadr programshareholder portal downloadsfinancial reportspresentationscsr reportsfact sheetimage archivecontactir policy careerscareersbavarian nordic offers a challenging international working environment in which job satisfaction and personal growth have a high priority.read moreworking with usour valuesour employee philosophy meet our employeeskvistgaard denmarkmartinsried germany the recruitment processjob openingscontactdenmarkgermanyjob openings about usabout usbavarian nordic is a fully integrated biotechnology company focused on the development manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.read more first half report 2016wednesday august 17 2016 . read more news & events news october 10 2016bavarian nordic announces initiation of phase 2 combination trial of prostvac and ipilimumab in patients with localized prostate cancerseptember 29 2016bavarian nordic announces presentation of phase 1 data for its rsv vaccine at international rsv symposiumseptember 28 2016bavarian nordic appoints christopher heery m.d. as chief medical officer view more investorstock price237 .00 last dkk 8.00 change dkk share information follow us contact 45 33 26 83 83 info bavarian nordic.com about bavarian nordic is a fully integrated biotechnology company focused on the development manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases . our locations denmark kvistgaard germany martinsried usa redwood city ca usa washington dc 2016 bavarian nordic disclaimer privacy cookies sitemap